# Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients

> **NCT05860244** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 36 (estimated)

## Conditions studied

- Walking Capacity
- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Salbutamol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05860244
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-09
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05860244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05860244, "Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05860244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*